Cognitive Rehabilitation for Cancer Survivors with Perceived Cognitive Impairment

Phase 3

• Conditions: Invasive solid tumour cancers; Self-reported cognitive deficit post-chemotherapy; Cancer - Any cancer; Mental Health - Studies of normal psychology, cognitive function and behaviour

• Registration Number: ACTRN12612001041842
• Lead Sponsor: The University of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-09-28
• Study Completion: 2022-02-11
• Last Update Posted: 19 April 2022

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

1Diagnosis of invasive solid tumour cancer for which definitive treatment was performed within the last 5 years
2Completed at least 3 cycles of chemotherapy
3Aged >17 years
4A NO” response recorded for the Single Item Cognitive Impairment Question
5Speak fluent English and read to a year 8 standard.
6Give written informed consent.
7Chemotherapy, radiotherapy, immunotherapy (e.g. trastuzumab and/or lapatinib) received must have been completed at least 6 months prior to randomisation.
8Hormonal treatment (including tamoxifen or an aromatase inhibitor) is permitted as long as treatment has been commenced at least 4 weeks prior to randomisation and is not likely to be ceased within 6 months of randomisation.

Exclusion Criteria

1, ECOG Performance Status of > 2
2, Any evidence of extra-nodal metastatic disease.
3, Any major pre-existing neurological condition, co-morbidity, psychiatric history or substance abuse that could interfere with their ability to perform cognitive testing.
4, Prior malignancy within the last 5 years (other than non-melanomatous skin cancer or cervical cancer in-situ) or previous chemotherapy other than adjuvant or neoadjuvant breast cancer treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified